OPTICROM
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTICROM is an ophthalmic solution approved in 1984 for eye-related indications, delivered as topical drops. The exact mechanism of action and therapeutic indication are not publicly specified in available data, but the formulation suggests treatment of allergic or inflammatory ocular conditions. As a small-molecule solution, it represents a traditional ophthalmology therapeutic approach.
LOE Approaching
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30/100), indicating defensive commercial strategy and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPTICROM currently has zero linked job openings, reflecting its mature market status and limited growth investment. Career opportunities are concentrated in defensive commercial roles rather than launch or expansion initiatives.
Brand ManagerField Sales Representative
Worked on OPTICROM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.